Sign in

NCT03301493Completed

Genomic Testing and Resulting Medical Decisions

The Use of Genomic Testing and the Resulting Medical Decisions According to Target Identification

Source: ClinicalTrials.gov · Last updated 10 Apr 2025

Brief summary (registry, in English)

There is no evidence available about which molecular profiling methods are currently used for cancer patients in Austrian clinical practice. The construction of the registry proposed as a completely independent research endeavor, will be helpful for scientific evaluation and the establishment of highly credible data.

Status (registry)
Completed
Study type
Observational
Enrollment
1500 (actual)
First submitted
22 Sept 2017
Start date
30 Mar 2017
Primary completion date
31 Dec 2023
Lead sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie
NCT number
NCT03301493

What you commit to

  • Study type: Observational
  • Participants enrolled: 1500
  • From 30 Mar 2017 to the primary completion date, 31 Dec 2023
  • 11 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Due to the non-interventional design of the registry there are no specific exclusion criteria.

Who the study is looking for

  • This registry will include cancer patients for which broad genomic profiling is indicated as assessed by the medical need and as deemed appropriate by the physician, for example
  • cancer with high mutational load and suspicion of regular or frequent formation of neoantigens
    • skin, lung, stomach, esophagus, colorectum, bladder, uterus, cervix, liver, head and neck, kidney, breast
    • lymphoma B-cell
  • any other neoplastic disease where molecular targeting is performed but treatment fails
  • cancer of unknown primary origin (CUP)
  • planned or already carried out comprehensive genomic testing as of Jan 1, 2016 note: this registry will not initially register patients who are tested for only 1-5 mutations by conventional means, but patients undergoing genomic profiling based on NGS)
  • a patient´s signed informed consent
  • Patients ≥ 18 years of age

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (11)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Innere Medizin II, LKH Feldkirch
Coordinator of this site? Confirm its status
FeldkirchAustriaUnknown status
Medizinische Universitaet Graz, Univ.-Klinik f. Innere Medizin, Onkologie
Coordinator of this site? Confirm its status
GrazAustriaUnknown status
Medizinische Universität Innsbruck
Coordinator of this site? Confirm its status
InnsbruckAustriaUnknown status
Universitatsklinikum Krems
Coordinator of this site? Confirm its status
KremsAustriaUnknown status
BHS Linz: Interne I: Internistische Onkologie, Hämatologie und Gastroenterologie
Coordinator of this site? Confirm its status
LinzAustriaUnknown status
IIIrd Medical Department, Private Medical University Hospital Salzburg
Coordinator of this site? Confirm its status
SalzburgAustriaUnknown status
Universitätsklinikum St. Pölten
Coordinator of this site? Confirm its status
Sankt PöltenAustriaUnknown status
Medizinische Universität Wien
Coordinator of this site? Confirm its status
ViennaAustriaUnknown status
Salzkammergut-Klinikum Vöcklabruck
Coordinator of this site? Confirm its status
VöcklabruckAustriaUnknown status
Klinikum Wels-Grieskirchen GmbH
Coordinator of this site? Confirm its status
WelsAustriaUnknown status
St. Vinzenz Krankenhaus Betriebs GmbH
Coordinator of this site? Confirm its status
ZamsAustriaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.